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Introduction
Periodontal disease develops when bacteria of the dental plaque migrate from the dental root hard tissues to nearby soft tissues. This results in chronic inflammation leading to destruction of the periodontal ligament and the alveolar bone that supports the teeth. The process by which a generally benign biofilm transforms into pathological periodontitis is complex and remains poorly understood. However, the presence of one particular species, the Gram-negative anaerobe Porphyromonas gingivalis, is considered to be an indicator of progression of chronic periodontitis [1, 2] . Periodontal disease, and specifically the presence of P. gingivalis, are risk factors for cardiovascular disease, aspiration pneumonia and low birth weight [3] [4] [5] . A wide array of virulence factors have been described for P. gingivalis that reflect the different processes by which the bacterium transforms from a commensal organism to a pathogen: biofilm formation, anaerobic growth, adhesion, suppression/activation of inflammatory responses, invasion, tissue degradation and intracellular survival in gingival epithelial cells and host immune cells (reviewed by [6, 7] ). P. gingivalis produces a unique set of proteases that are believed to be required for nutrient provision during its compulsory asaccharolytic growth, but may also contribute to evasion of the host immune system, adhesion and degradation of extracellular matrix [8] [9] [10] . One of these proteases is P. gingivalis dipeptidyl peptidase 4 (pgDPP4). The gene encoding pgDPP4 was first sequenced and cloned in 2000 [11] , and the protein is secreted but remains associated with the membrane [12] .
PgDPP4 is a proline-specific dipeptidyl peptidase that cleaves peptides related to immune responses and inflammation in vitro. Evidence suggests pgDPP4 interacts with extracellular matrix proteins such as fibronectin and collagen, thereby promoting collagen degradation by matrix metalloproteinases activated by the host inflammatory response [13, 14] . Mice injected with a DPP4-deficient mutant strain developed less abscesses and survived longer than mice injected with the wild type (W83) strain [11] , implicating pgDPP4 as a virulence factor.
Transfection with recombinant pgDPP4 restored virulence, while a catalytically impaired DPP4 only partially restored the wild type phenotype [15] . Moreover, clinical isolates of P.
gingivalis strains with high DPP4 expression had a higher capacity for biofilm formation and were more infective in a mouse abscess model [16] . pgDPP4 belongs to the same family of proteases (prolyl oligopeptidase family, S9 clanB, MEROPS database) as human DPP4 (hDPP4), with which it shares 32% amino acid sequence identity. This indicates a similar topology and enzymatic mechanism. Even though the catalytic residues and side chains forming the primary substrate-binding site are conserved, we noticed significant differences in the potency of selected inhibitors, and in the substrate specificity, between the bacterial and human enzymes [17] . Following preliminary crystallization experiments [18] , one of the aims of the present study was to identify the origins of these differences in the structure of pgDPP4, as a prerequisite to developing more specific inhibitors in the future. Both enzymes likely share substrates present in the oral cavity, the gingival epithelium and sites of inflammation.
In humans, the inhibition of DPP4 catalyzed inactivation of incretins (intestinal peptides regulating insulin secretion) proved to be successful for the treatment of type 2 diabetes [19] .
Over the last two decades, numerous DPP4 inhibitors have been synthesized, screened and tested for their antidiabetic activity, while other compounds have been prepared to address selectivity and to investigate the roles of several related peptidases. Thus, there exists a sizable collection of mammalian DPP family inhibitors available for screening against other targets. The collection used in the present work includes compounds that have been developed and characterized at the University of Antwerp during a longstanding research program on various peptidases, including DPP4, DPP2, DPP8, DPP9, fibroblast activating protein-α (FAP) and prolyl oligopeptidase (PREP). They are based on several chemical scaffolds [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . The collection also includes reference compounds, such as the antidiabetic drugs 6 sitagliptin, vildagliptin and linagliptin, and prototypical DPP2, DPP8/9 and FAP inhibitors.
The aim of this study was to screen the collection of compounds present at the University of Antwerp. Additionally, an assortment of secreted peptides present at the University of Leuven was used as a substrate collection in order to investigate structure-function relationships in the active site of pgDPP4.
Results

Structural alignment of pgDPP4 and hDPP4
The overall structural similarity between both DPP4s is shown in Figure 1 . A sequence alignment with species-specific numbering is shown in the supplementary material. The active sites of pgDPP4 and hDPP4 are evidently similar. Direct transfer of the coordinates of the hDPP4 structures with different ligands into the active site of the aligned pgDPP4 structure (i.e. docking of ligands in pgDPP4 active site) reveals similar substrate binding pockets for both DPP4 enzymes. Table S1 in the supplementary material provides a list of all hDPP4 structures used in this work, together with references to the Protein Structure Database (PDB) and the original publications.
A narrow but deep S1-pocket is located next to the catalytic Ser-593 (adopting pgDPP4 numbering), and direct mapping of the many co-crystallized ligands from the human structures into the pgDPP4 structure reveals that this pocket could potentially accommodate a proline-moiety like the pyrrolidine ring of the Val-pyrrolidide or a phenyl or halogensubstituted phenyl of many other ligands, including vildagliptin and sitagliptin (Table S1 ).
The residues flanking the S1-pocket are identical in the human and P. gingivalis enzymes.
The S1-pocket is hydrophobic; lipophilic residues Tyr-594, Tyr-625, Tyr-629, Trp-622 and Val-619 are located within 4 Å of the pyrrolidine ring of the co-crystallized Val-pyrrolidide ligand from the human structure (PDB ID A3M) A visual representation of the S1 pocket can be found in Figure 4 of the paper by Rasmussen et al., 2002 [34] .
In both DPP4 enzymes, the positive charge of the amino terminus of the substrate peptide is neutralized by the negative charges from two glutamate residues flanking the S2-pocket, namely . The location of both residues is identical in the two enzymes.
Almost all analyzed ligands from the human DPP4 crystals contain a functionality that mimics the interaction with the two S2-flanking glutamates through a primary or secondary amine. The only exception is the diisopropyl fluorophosphate ligand (DFP) from the 1TKR crystal structure, since this ligand does not occupy the S2-pocket at all. Also noteworthy is the binding mode of compound 5AP (Pdb: 1RWQ, Table S1 ), since in addition to the normal interaction of the glutamates with the benzylamino group of 5AP, an additional hydrogen bond is formed between the aniline on the pyrimidine moiety and the backbone carbonyl of Many of the co-crystallized ligands in hDPP4 bind well beyond the S2-pocket in a subsite labeled as "S2-extensive". According to structural analysis performed by Nabeno and coworkers, this pocket is not defined in other related proline specific peptidases such as DPP8, DPP9 and fibroblast activating protein-α [35] . In hDPP4, the S2-extensive pocket is flanked by residues Val-207, Ser-209, Phe-357 and Arg-358 (hDPP4 numbering). Based on the structural alignment, these residues are not completely conserved in pgDPP4. corresponds to Phe-197 in pgDPP4, the human Ser-209 corresponds to Gly-198 of pgDPP4 (with a deletion of the human Phe-208 for which there is no matching alternative in pgDPP4), Arg-358 corresponds to Asp-329 in pgDPP4, and the human Phe-357 has no immediate equivalent in pgDPP4 which makes the human S2-extensive pocket somewhat smaller (Figure 3) .
The amino acid differences between the human and P. gingivalis S2-extensive pocket might have implications for the design of selective drugs. It could be argued that ligands that take advantage of these local differences of the S2-extensive pocket might be more selective against a particular DPP4 form. A number of hDPP4 inhibitors have been described that form interactions with Phe-357 and Arg-358 of the human enzyme. These residues are located along the same side of the pocket. For example, compound S14 (Pdb: 2FJP) forms a hydrogen bond with Arg-358 and also forms a stacking interaction with the phenyl ring of Phe-357. 
Screening of the inhibitor collection
A collection of 450 compounds was screened, including clinically used DPP4 inhibitors and some reference compounds, shown in Scheme 1 and Table 1 . Most of the compounds were dipeptide derivatives. Of these 81 exhibited more than 50% inhibition at a concentration of 100 µM, and 33 displayed greater than 50% inhibition at 10 µM. As a rule, IC50 values were only determined for compounds that gave more than 50% inhibition at 10 µM. For the latter compounds IC50 values ranged between 10 and 0.05 µM (supplementary material, Table S2 ). Compounds with a protected amino terminus, targetting PREP and FAP [22, 23, 25, 30] , showed no inhibition, confirming that pgDPP4 is a true dipeptidyl peptidase.
Compounds with an isoindoline derivative in the P1 position (which confers selectivity towards DPP8/9) [33] in general did not appreciably inhibit pgDPP4, and neither did compounds with a phosphonate moiety attached to P1 (irreversible DPP inhibitors) [31] . The remaining compounds were assigned to two classes, based on their structural scaffold. Class 1 contains compounds with a variation of amino acids in P2 in combination with pyrrolidine or variations thereon in P1. Class 2 compounds have a variation in P2, not limited to natural amino acids, and have combinations of substitutions on the pyrrolidine ring. Still in class 1, it was found that at the P1 position the five-membered pyrrolidide ring is optimal for both DPP4s but the slightly larger piperidine provides some selectivity for pgDPP4. Ile-4-hydroxy-pyrrolidide was present in the inhibitor library but its affinity for pgDPP4 (and hDPP4) is at least 10-fold lower than Ile-pyrrolidide. Larger structures in P1 lead to loss of affinity. Isoindoline, which conveys selectivity for DPP8/9, generally gives poor inhibition of pgDPP4. Substituents on the pyrrolidide ring increase the affinity for the pgDPP4 active site. It has been known for some time that electrophiles such as a nitrile group on C2 can ameliorate the IC50 for all DPPs [29] . This is also the case for pgDPP4. The combination of an azide group at position 3 improves binding to pgDPP4 more than to hDPP4, but the resulting compounds still have a low selectivity.
Structure-activity relationships (SAR) of inhibitors: S1 and S2 binding sites
Class 2 includes 2-cyano,4-azido-pyrrolidides with isoleucine, allo-isoleucine, lysine and glutamate or aspartate derivatives at the P2 position. In this class, the most selective pgDPP4 inhibitors were Lys-3-azo-2-cyano-pyrrolidide and N-2-naphtyl-Lys-4-azo-2-cyanopyrrolidide, which were seven-fold more active against pgDPP4 than hDPP4. Large substituents on the lysine side chain appear to be easily accommodated, a property shared with human DPP2 and DPP8/9. When polar groups are introduced in the P2 side chain in a series of substituted Asp or Glu derivatives, there is a strict selectivity for a two-carbon spacer between the Cα and the carbonyl carbon atom. The resulting SAR is given in Table 2 , and 
Structure-activity relationship in the S' substrate binding sites
Most of the compounds screened vary in the P1 and P2 positions. Interactions with the S' substrate binding sites were not considered. There is one structure of hDPP4 (Pdb: 1NU8) that contains the inhibitor/substrate Ile-Pro-Ile. In this structure the C-terminal isoleucine side chain is accommodated in the S1' site. Reasoning that the extended substrate recognition site may reach further than the S1' site, we investigated the substrate specificity of pgDPP and hDPP with a collection of 123 peptides (4 to 25 amino acids long) containing an N-terminal Xaa-Pro/Ala/Ser/Gly sequence (in almost equal proportion). In the conditions tested, 23 of these were cleaved by hDPP4 and 32 were hydrolyzed by pgDPP4. Pro and Ala on the P1 position determine the substrate specificity. None of the Xaa-Ser-containing peptides were cleaved, and only one Xaa-Gly peptide was processed. Peptides with a Xaa-Pro-Pro or XaaAla-Pro motif were not cleaved either. The observed differences in the number of peptides cleaved, along with the frequency plots, indicate subtle differences between the DPP4s. pgDPP4 cleaved peptides have a higher frequency of aliphatic/hydrophobic side chains (V, F, L) in the P1' position than the average peptide in the collection. Eleven peptides were cleaved by pgDPP4 but not by the human counterpart. Of these, five peptides had a penultimate proline and six contained one or two prolines in the P2' to P4' region. The P2-P2' sequences of the peptides cleaved by pgDPP4 were used to construct a selectivity matrix ( Table 3 ).
Discussion
The new crystal structure of pgDPP4 provides experimental evidence that, despite the low sequence identity, this bacterial enzyme has the same overall structure and catalytic mechanism as the human homolog. All key features of the catalytic machinery are structurally conserved, including the S1 pocket accommodating the proline, the catalytic triad, the oxyanion hole required for stabilisation of the transition state and tetrahedral intermediates, the two glutamates that bind the positively charged N-terminus of the substrate and the S1' pocket that maintains a sharp bend in the substrate's backbone. All these features have been described in the hDPP4 literature [34] [35] [36] . This structural conservation is also reflected in the fact that, with a few exceptions, both enzymes cleave the same substrates in a biologically relevant peptide collection (Table 3) . However, there are local differences in areas that are not within reach of the side chains of the natural substrates but are occupied by synthetic inhibitors of hDPP4, notably the S2-extensive pocket (Figure 3 ). Even though it was not possible to obtain ligand-bound structures in the specific crystallisation conditions, the pgDPP4 structure proved instrumental in understanding the specificty of inhibitors and may be usefull in future drug development projects targetting other proline specific dipeptidyl peptidases.
The conservation of the catalytic machinery provides an explanation for the increase in potency when a reactive group, a "warhead", is present on the P1 of the inhibitors. In Table 2 and Figure 4 , one observes a 10-fold increase in potency when a carbonitrile group is placed on the C2 of the pyrrolidide ring. The nitrile group is considered to sit in the active site as a transition state analog where the oxyanion hole provides stabilisation of a negative charge on the nitrogen, thus activating the carbon atom for a nucleophilic attack by the active site serine.
This significantly enhances binding compared to compounds that lack the warhead and are otherwise the same. For hDPP4 and PREP, this has been observed on numerous occasions since the first reports in the 1990's [37] . This type of inhitor is often called covalent, because in the crystal structures there is a short contact between the carbonitrile carbon atom and the oxygen of the site chain of the catalytic serine. From enzyme kinetics one cannot deduce whether these compounds form a covalent bond, since they behave as reversible competitive inhibitors. Very potent compounds sometimes display slow-binding and hyperbolic kinetics [38, 39] . However, since the pgDPP4 structure has no ligand and inhibition was essentially instantaneous, it remains unknown whether a covalent interaction occurs between the catalytic serine and the carbonitrile containing compounds of this study. Assuming that all the compounds are reversible competitive inhibitors, and considering that the IC50 values were determined at a substrate concentration equal to the Km, the IC50 values are a measure of the inhibition constants (Ki), allowing direct comparison of the potency between the different enzymes.
The pgDPP4 pharmacophore that emerged from the screening is shown in Figure 5 . In P1 a pyrrolidine is preferred, but in combination with certain P2 components, isoindoline and pyridine are accepted (for example 43, 83, 84 and 64 in Table S2 ) [17] . This is not the case for hDPP4 so it may be concluded that the S1 pocket of pgDPP4 is slightly larger than that of hDPP4, but not as large as that of DPP9 which prefers an isoindoline [33] . The carbonitrile warhead improves potency, but this is not specific for pgDPP4 because it is also observed with hDPP4, DPP9, DPP8 and DPP2 [29] . It requires (S) stereochemistry, like the peptide backbone of the natural substrates. A boronic acid in this position also improves potency (but not selectivity, 3 Table 1 ) and contrary to hDPP4 and DPP8, diphenyl phosphonates are ineffective [17, 31] , a phenomenon that is difficult to rationalize from the structure. The introduction of an azide group on the C4 affords a specific effect that is absent with hDPP4 but present with DPP9. Consequently, compounds 13 -17 have a higher potency for pgDPP4 than for hDPP4 but the selectivity towards DPP9 does not change much. In Figure 4 , the line representing DPP9 inhibition is more or less parallel with the diagonal, indicating that the contribution of the azide substituent is independent from the P2 component. The azide substituent has to be in cis relative to the carbonitrile (17 in Table 2 and 46 in Table S2 ). In previous studies inhibitors were optimized for binding to DPP9 [21, 29, 30, 32] . The results of the screening show an overlap between the pharmacophores of pgDPP4 and DPP9 with respect to the azide and the P2 component. The best P2 residues are large, often with a nitrogen atom on a carbon spacer and substituted with bulky or aromatic groups (16, 18 in Table 2 and 69, 72, 73 in Table S2 ). The most likely explanation is that they bind specifically in the S2-extensive pocket which is deeper than in hDPP4 and has a different charge distribution ( Figure 3 ). Since there is only a homology model but no crystal structure of DPP9 in the public domain, the results strongly suggest that the S2-extensive binding site could be targetted with likely success in DPP9 (and DPP8) [40] . DPP9 inhibitors are currently used to investigate a potential role of DPP9 in inflammation but it is too soon to predict a use in therapy [41, 42] .
By including the peptide collection, this study addressed the potential of the S' binding sites for selectivity. However, from the crystal structure, there appears little evidence that enzyme-substrate interactions occur beyond the S2' site. The observed differences between human and pgDPP4 probably derive from structural properties of proline-containing peptides.
Knowledge of the catalytic potency of serine proteases relies largely on historical studies with chymotrypsin and related proteases. How the different S9 family members deal with the intricacies of the chemistry required to cleave a post-proline bond therefore deserves further investigation [39] .
In this study, we compared P. gingivalis DPP4 with human DPP4, and the results may be extrapolated to other bacterial DPP4s. The structure of at least one other bacterial DPP4 has been studied, namely the homolog from Stenotrophomonas maltophilia, which has the ability to hydrolyze peptide bonds following 4-hydroxy-proline, as are found in collagen (PDB ID 2ECF) [43] . As our knowledge of bacterial genomes is rapidly expanding, it is very likely that other bacterial DPP4s will be discovered [44] , and it may be interesting to verify whether they bind to the compounds currently used as antidiabetics. Although it is not completely clear at the moment how bacterial DPPs could be exploited as targets, this work at least offers a starting point for the development of specific compounds for bacterial enzymes; or a secundary use for existing drugs in the future.
Conclusion
Concluding, hDPP4 and pgDPP4 have very similar overall structure and substrate specificity.
Nevertheless, screening of the available inhibitor collection and docking of compounds in the pgDPP4 active site revealed that the clinically used DPP4 inhibitors have little affinity for pgDPP4. On the other hand, there is a certain overlap between the pgDPP4 and DPP9 pharmacophores. The crystal structure of pgDPP4 provides a starting point for the optimisation of inhibitors in the future and for an increased understanding of inhibitor selectivity for proline specific peptidases in general.
Experimental section
Materials
Gly-Pro-p-nitroanilide was purchased from Sigma (Diegem, Belgium). Inhibitor synthesis was described in the original publications [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . Synthetic peptides were acquired from Thermo Scientific.
Cloning, expression and purification of recombinant pgDPP4 were performed as previously described [18] . Assays for human DPP4 and bovine DPP9 were performed as described previously [29] .
Activity and inhibition measurements
Enzyme-catalyzed peptide hydrolysis
The University of Leuven collection of putative neuropeptides and endocrine peptides was based on a combination of peptidomics results and bioinformatics [45, 46] . Peptides with a penultimate proline, alanine, glycine or serine were chosen for this study. 
Crystallization, structure determination, model building and refinement
Recombinant pgDPP4 was crystallized as previously described [18] using the hangingdrop vapour-diffusion technique in 40% 2-methyl-2,4-pentanediol and 100 mM TRIS-HCl pH 8.0. Despite pgDpp4 sharing only 32% sequence identity with the porcine and human enzymes, partial molecular replacement was successful using the structures of these enzymes as search models. Diffraction data were therefore collected from selenomethionine-derived PgDpp4 crystals for structure determination by Multiwavelength Anomalous Dispersion (MAD). Crystals were removed from the crystallization drop using a nylon loop, transferred directly to liquid nitrogen, and stored until needed. X-ray diffraction data to a resolution of 2.7 Å were collected from selenomethionine-derived crystals at peak, inflection point and remote wavelengths on beam line ID14-4 at the ESRF, Grenoble, following a fluorescence scan. All data were indexed, integrated and scaled with the HKL package [47] . Following anomalous Fourier synthesis from the molecular replacement partial solution using PHASER [48] , the program SOLVE [49] successfully found 21 of the 25 selenium sites present in each of the eight subunits. After automatic model building using RESOLVE [49] and density modification with BUCCANEER [50] , it was clear that some parts of some subunits were largely disordered. We therefore abandoned this attempt at structure solution and pursued a different crystal form. New crystallization screens were set up with a fresh batch of protein and crystals were successfully grown in condition H10 of the MORPHEUS crystallization screen [51] resolution at our in-house X-ray source, and crystals belonged to the tetragonal space group P41212 with one molecule (half a dimer) in the crystallographic asymmetric unit. Data were processed by XDS [52] and CCP4 [53] , and the structure was solved by PHASER [48] , which is reported here. The resulting model was improved by iterative rounds of refinement and model building using REFMAC5 and O [54, 55] . Water molecules were added to the atomic model automatically using ARP-w-ARP [56] at the positions of large positive peaks in the difference electron density, only at places where the resulting water molecule fell into an appropriate hydrogen bonding environment. Data processing and refinement statistics are given in Table 4 . The final model contains residues 21-723, and was visualized in, and figures produced using, PyMol [57] .
The PDB ID is 5OLJ.
Modeling and docking
The crystal structures of many human DPP4 (hDPP4) proteins, co-crystallized with substrate analogues or other types of inhibitors, were taken from the PDB. The structures used are listed in supplementary material Table S1 . The coordinates of the catalytic triad residues from each of these human DPP4s were structurally aligned onto the corresponding pgDPP4
coordinates and the derived transformation matrices were subsequently applied to each of the co-crystallized ligands.
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